Intermediate Alpha-1 Antitrypsin Deficiency Can Play a Role in Pulmonary Exacerbation?
DOI:
https://doi.org/10.12974/2312-5470.2021.07.01Keywords:
AATD, COPD, Respiratory, Deficiency, Antitrypsin.Abstract
Background: Alpha-1 antitrypsin deficiency is generally suspected in young patients with pulmonary emphysema or chronic obstructive pulmonary disease (COPD). Patients often suffer from diagnostic delays or are misdiagnosed, for example, with COPD, asthma, or airway hyperresponsiveness because of the nonspecific nature of respiratory symptoms recognised with Alpha-1 antitrypsin deficiency (AATD). These pathologies develop in homozygous patients (both compromised alleles) with severely deficient protein; however, they are also frequently observed in heterozygous patients (only one compromised allele) for the gene mutation with a more or less deficient protein and functional anatomical damage of varying severity depending on the type of mutation and the exposure to environmental risk factors and/or professional that can trigger the repeated injurious inflammatory process. Case Description: We describe two cases of late diagnosis of alpha-1 antitrypsin deficiency, with many exacerbations and intermediate level of alpha-1 antitrypsin. Due to the peculiar clinical history, and the PLowell rare mutation, although intermediate AATD, the patients were subjected to replacement therapy and they obtained clinical improvement. Discussion: Both the cases carried a heterozygous PLowell mutation representing two interesting and rare examples of clinical cases with double heterozygosity. The presence in the other AAT allele of the S-mutation in the first case and a concomitant presence of another mutation in the cystic fibrosis gene in the second case contributed to the protease-antiprotease imbalance and, despite intermediate AATD, was the probable cause of the numerous exacerbations. Conclusion: Alpha-1 antitrypsin deficiency should always be suspected in patients with respiratory disease and an unclear or complex clinical history. It may be useful to recognize and evaluate treatment even outside the established parameters, in selected cases.
References
Torres-Durán M, Lopez-Campos JL, Barrecheguren M, et al. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis. 2018;13(1):114. https://doi.org/10.1186/s13023-018-0856-9
Demeo DL, Sandhaus RA, Barker AF, et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax. 2007;62(9):806-813. https://doi.org/10.1136/thx.2006.075846
Jonigk D, Al-Omari M, Maegel L, et al. Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci U S A. 2013;110(37):15007-15012. https://doi.org/10.1073/pnas.1309648110
Cosio MG, Bazzan E, Rigobello C, et al. Alpha-1 Antitrypsin Deficiency: Beyond the Protease/Antiprotease Paradigm. Ann Am Thorac Soc. 2016;13 Suppl 4:S305-310. https://doi.org/10.1513/annalsats.201510-671kv
Eden E. Asthma and COPD in alpha-1 antitrypsin deficiency. Evidence for the Dutch hypothesis. COPD. 2010;7(5):366-374. https://doi.org/10.3109/15412555.2010.510159
DeMeo DL, Campbell EJ, Barker AF, et al. IL10 Polymorphisms Are Associated with Airflow Obstruction in Severe α1-Antitrypsin Deficiency. Am J Respir Cell Mol Biol. 2008;38(1):114-120. https://doi.org/10.1165/rcmb.2007-0107oc
Vignola AM, Bonanno A, Profita M, et al. Effect of age and asthma duration upon elastase and alpha1-antitrypsin levels in adult asthmatics. Eur Respir J. 2003;22(5):795-801. https://doi.org/10.1183/09031936.03.00112302
Castaldi PJ, DeMeo DL, Kent DM, et al. Development of predictive models for airflow obstruction in alpha-1-antitrypsin deficiency. Am J Epidemiol. 2009;170(8):1005-1013. https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a3499
O’Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW, START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009;179(1):19-24. https://doi.org/10.1164/rccm.200807-1126oc
Rodriguez F, Jardí R, Costa X, et al. Rapid screening for alpha1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease using dried blood specimens. Am J Respir Crit Care Med. 2002;166(6):814-817. https://doi.org/10.1164/rccm.2203025
Bornhorst JA, Calderon FRO, Procter M, Tang W, Ashwood ER, Mao R. Genotypes and serum concentrations of human alpha-1-antitrypsin “P” protein variants in a clinical population. J Clin Pathol. 2007;60(10):1124-1128. https://doi.org/10.1136/jcp.2006.042762
McElvaney NG. Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency. 2016;13:6. https://doi.org/10.1007/978-3-319-23449-6_6
Witt H, Kage A, Luck W, Becker M. Alpha1-antitrypsin genotypes in patients with chronic pancreatitis. Scand J Gastroenterol. 2002;37(3):356-359. https://doi.org/10.1080/003655202317284282
14 Greulich T, Vogelmeier CF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis. 2016;10(1):72-84. https://doi.org/10.1177/1753465815602162
Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75(5):397-415. https://doi.org/10.1016/b978-0-12-803942-7.00002-7
Ferrarotti I, Carroll TP, Ottaviani S, et al. Identification and characterisation of eight novel SERPINA1 Null mutations. Orphanet J Rare Dis. 2014;9:172. https://doi.org/10.1186/s13023-014-0172-y
Sandhaus RA, Turino G, Brantly ML, et al. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obstr Pulm Dis. 2016;3(3):668-682. https://doi.org/10.15326/jcopdf.3.3.2015.0182
Rahaghi FF, Monk R, Ramakrishnan V, Beiko T, Strange C. Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry. Int J Chron Obstruct Pulmon Dis. 2020 Dec 3;15:3193-3199. PMID: 33299307; PMCID: PMC7721109. https://doi.org/10.2147/copd.s263725
Sandhaus RA, Turino G, Brantly ML et al. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obstr Pulm Dis. 2016 Jun 6;3(3):668-682. PMID: 28848891; PMCID: PMC5556762. https://doi.org/10.15326/jcopdf.3.3.2015.0182
Marciniuk DD, Hernandez P, Balter M et al.; Canadian Thoracic Society COPD Clinical Assembly Alpha-1 Antitrypsin Deficiency Expert Working Group. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2012 Mar-Apr;19(2):109-16. Erratum in: Can Respir J. 2012 Jul-Aug;19(4):272. PMID: 22536580; PMCID: PMC3373286. https://doi.org/10.1155/2012/920918
Annunziata, A.; Ferrarotti, I.; Coppola et al. Alpha-1 Antitrypsin Screening in a Selected Cohort of Patients Affected by Chronic Pulmonary Diseases in Naples, Italy. J. Clin. Med. 2021, 10, 1546. https://doi.org/10.3390/jcm10081546
Kueppers F. Clinical presentations of four patients with rare Alpha 1 Antitrypsin variants identified in a single US center. Respir Med Case Rep. 2021;32:101345. https://doi.org/10.1016/j.rmcr.2021.101345
